（-）-去甲丙咪嗪治疗期间的单胺氧化酶活性：人脑尸检研究 - Suppr

Suppr

超能文献

Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.

作者信息

Riederer P, Youdim M B, Birkmayer W, Jellinger K

出版信息

Adv Biochem Psychopharmacol. 1978;19:377-82.

PMID:696465

Abstract

摘要

相似文献

Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.（-）-去甲丙咪嗪治疗期间的单胺氧化酶活性：人脑尸检研究

Adv Biochem Psychopharmacol. 1978;19:377-82.

Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.单胺氧化酶B抑制剂的药理学：（-）司来吉兰在帕金森病中的作用方式。

J Neural Transm Suppl. 1986;22:91-105.

(-)Deprenyl in the treatment of Parkinson's disease.（-）司来吉兰治疗帕金森病。

Clin Neuropharmacol. 1982;5(2):195-230. doi: 10.1097/00002826-198205020-00004.

Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.单胺氧化酶A和单胺氧化酶B在人脑中的定位：理解L-司来吉兰治疗作用的一个步骤。

Adv Neurol. 1987;45:111-8.

Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.司来吉兰是一种用于帕金森病长期治疗的脑单胺氧化酶B（MAO-B）选择性抑制剂。

Br J Clin Pharmacol. 1980 Jan;9(1):98-9. doi: 10.1111/j.1365-2125.1980.tb04805.x.

[Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].

Riv Neurol. 1985 Jan-Feb;55(1):46-52.

The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.帕金森病的病理生物学：多巴胺能神经元衰老的生化方面

J Neural Transm Suppl. 1983;19:89-103.

Are there MAO inhibitors specific for dopamine metabolism?是否存在对多巴胺代谢具有特异性的单胺氧化酶抑制剂？

Adv Biochem Psychopharmacol. 1977;16:349-58.

The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.重复剂量的（-）司来吉兰对单胺能传递动力学的影响。与氯吉兰的比较。

Pol J Pharmacol Pharm. 1986 Jan-Feb;38(1):57-67.

Selegiline for Parkinson's disease.司来吉兰用于帕金森病。

Am Fam Physician. 1990 Feb;41(2):589-91.

引用本文的文献

MAO-inhibitors in Parkinson's Disease.MAO 抑制剂在帕金森病中的应用。

Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31.

Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.基因组学和蛋白质组学研究调查抗帕金森病药物雷沙吉兰与司来吉兰作用机制的差异，在大鼠中脑。

J Neural Transm (Vienna). 2009 Nov;116(11):1457-72. doi: 10.1007/s00702-009-0225-x. Epub 2009 Apr 25.

Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.左旋多巴和司来吉兰给药后人体脑脊液中多巴胺和3,4-二羟基苯乙酸（DOPAC）水平的变化。

J Neural Transm. 1983;58(3-4):299-304. doi: 10.1007/BF01252815.

Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Drugs. 1990 May;39(5):646-51. doi: 10.2165/00003495-199039050-00002.

Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.

J Neural Transm. 1978;43(3-4):279-86. doi: 10.1007/BF01246965.

On the mode of action of L-deprenyl in the human central nervous system.关于L-司来吉兰在人类中枢神经系统中的作用方式

J Neural Transm. 1978;43(3-4):217-26. doi: 10.1007/BF01246958.

The active centers of monoamine oxidase types "A" and "B": binding with (14C)-clorgyline and (14C)-deprenyl.

J Neural Transm. 1978;43(3-4):199-208. doi: 10.1007/BF01246956.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验